Bank of The Ozarks lowered its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 1.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,406 shares of the medical research company’s stock after selling 120 shares during the period. Bank of The Ozarks’ holdings in Thermo Fisher Scientific were worth $1,138,000 as of its most recent filing with the SEC.
A number of other large investors have also recently made changes to their positions in the stock. Norges Bank purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $534,860,000. Glenview Capital Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $516,388,000. C WorldWide Group Holding A S boosted its stake in shares of Thermo Fisher Scientific by 997.1% in the first quarter. C WorldWide Group Holding A S now owns 1,950,049 shares of the medical research company’s stock valued at $299,527,000 after buying an additional 1,772,300 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $107,251,000. Finally, NN Investment Partners Holdings N.V. boosted its stake in shares of Thermo Fisher Scientific by 458.2% in the first quarter. NN Investment Partners Holdings N.V. now owns 528,598 shares of the medical research company’s stock valued at $81,194,000 after buying an additional 433,898 shares during the last quarter. 87.15% of the stock is owned by institutional investors and hedge funds.
Shares of Thermo Fisher Scientific Inc (NYSE TMO) traded down 1.89% during mid-day trading on Tuesday, hitting $173.99. 1,648,460 shares of the stock were exchanged. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $182.87. The stock has a market cap of $67.86 billion, a PE ratio of 30.31 and a beta of 1.06. The stock’s 50 day moving average is $177.02 and its 200-day moving average is $164.40.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.27 by $0.03. The firm had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.03 earnings per share. On average, analysts anticipate that Thermo Fisher Scientific Inc will post $9.24 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.34%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is 10.45%.
ILLEGAL ACTIVITY WARNING: “Bank of The Ozarks Has $1.14 Million Position in Thermo Fisher Scientific Inc (NYSE:TMO)” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2017/08/08/thermo-fisher-scientific-inc-nysetmo-position-reduced-by-bank-of-the-ozarks-updated-updated-updated.html.
Several research analysts have commented on TMO shares. Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $186.00 to $192.00 and gave the stock an “overweight” rating in a report on Friday, April 28th. Barclays PLC restated an “overweight” rating and issued a $190.00 price objective (up from $175.00) on shares of Thermo Fisher Scientific in a report on Tuesday, May 9th. Deutsche Bank AG upped their price objective on shares of Thermo Fisher Scientific from $163.00 to $188.00 and gave the stock a “buy” rating in a report on Friday, April 28th. Leerink Swann set a $187.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, April 27th. Finally, Cowen and Company restated an “outperform” rating and issued a $185.00 price objective (up from $175.00) on shares of Thermo Fisher Scientific in a report on Saturday, April 29th. One analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $188.56.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 20,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the transaction, the chief executive officer now owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $176.26, for a total value of $440,650.00. Following the transaction, the chief financial officer now directly owns 37,790 shares in the company, valued at approximately $6,660,865.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,188 shares of company stock valued at $4,702,223. 0.49% of the stock is owned by company insiders.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.